U.S. Oncology Plans To Go Private Ahead Of Medicare Rx, But Seeking Other Bidders
This article was originally published in The Pink Sheet Daily
Executive Summary
The cancer care services company has worked out a $1.7 bil. buyout deal, but can actively solicit other offers until April 16. By going private, U.S. Oncology avoids wide fluctuations in its share price and possible future cuts in reimbursement.